Pacira BioSciences 株価情報 (NASDAQ: PCRX)

最新ニュース Pacira BioSciences (NASDAQ:PCRX) 株価情報

Pacira BioSciences

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.

Pacira BioSciences Inc

Here are three stocks with buy rank and strong value characteristics for investors to consider today, February 11th:
OMV Aktiengesellschaft OMVKY: This energy and chemicals company carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 4.5% over the last 60 days.
<div class="chart_embed">
<h3>OMV AG Price and Consensus</h3>
<a href="https://www.zacks.com/stock/chart/OMVKY/price-consensus-chart?icid=chart-OMVKY-price-consensus-chart"><img alt="OMV AG Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/f0/1739262717.png" style="height:264px; width:527px" title="" /> </a>
<a href="https://www.zacks.com/stock/chart/OMVKY/price-consensus-chart?icid=chart-OMVKY-price-consensus-chart">OMV AG price-consensus-chart</a> | <a href="https://www.zacks.com/stock/quote/OMVKY?icid=chart-OMVKY-price-consensus-chart">OMV AG Quote</a>
</div>
OMV has a price-to-earnings ratio (P/E) of 5.96, compared with 7.30 for the industry. The company possesses a <a href="https://www.zacks.com/style-scores-education/">Value Score</a>&nbsp; of A.
<div class="chart_embed">
<h3>OMV AG PE Ratio (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ttm#NYSE">TTM</a>)</h3>
<a href="https://www.zacks.com/stock/chart/OMVKY/fundamental/pe-ratio-ttm?icid=chart-OMVKY-fundamental/pe-ratio-ttm">TTM</a>)&quot; height=&quot;250&quot; src=&quot;https://staticx-tuner.zacks.com/images/charts/c9/1739262943.png&quot; title=&quot;&quot; width=&quot;493&quot; /&gt;
<a href="https://www.zacks.com/stock/chart/OMVKY/fundamental/pe-ratio-ttm?icid=chart-OMVKY-fundamental/pe-ratio-ttm">OMV AG pe-ratio-ttm</a> | <a href="https://www.zacks.com/stock/quote/OMVKY?icid=chart-OMVKY-fundamental/pe-ratio-ttm">OMV AG Quote</a>
</div>
Pacira BioSciences, Inc. PCRX: This non-opioid pain management and regenerative health solutions company carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its next year earnings increasing 21% over the last 60 days.
<div class="chart_embed">
<h3>Pacira BioSciences, Inc. Price and Consensus</h3>
<a href="https://www.zacks.com/stock/chart/PCRX/price-consensus-chart?icid=chart-PCRX-price-consensus-chart"><img alt="Pacira BioSciences, Inc. Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/18/1739262729.png" style="height:264px; width:568px" title="" /> </a>
<a href="https://www.zacks.com/stock/chart/PCRX/price-consensus-chart?icid=chart-PCRX-price-consensus-chart">Pacira BioSciences, Inc. price-consensus-chart</a> | <a href="https://www.zacks.com/stock/quote/PCRX?icid=chart-PCRX-price-consensus-chart">Pacira BioSciences, Inc. Quote</a>
</div>
Pacira has a price-to-earnings ratio (P/E) of 7.69, compared with 24.45 for the S&amp;P 500. The company possesses a Value Score of A.
<div class="chart_embed">
<h3>Pacira BioSciences, Inc. PE Ratio (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ttm#NYSE">TTM</a>)</h3>
<a href="https://www.zacks.com/stock/chart/PCRX/fundamental/pe-ratio-ttm?icid=chart-PCRX-fundamental/pe-ratio-ttm">TTM</a>)&quot; height=&quot;250&quot; src=&quot;https://staticx-tuner.zacks.com/images/charts/35/1739262962.png&quot; title=&quot;&quot; width=&quot;527&quot; /&gt;
<a href="https://www.zacks.com/stock/chart/PCRX/fundamental/pe-ratio-ttm?icid=chart-PCRX-fundamental/pe-ratio-ttm">Pacira BioSciences, Inc. pe-ratio-ttm</a> | <a href="https://www.zacks.com/stock/quote/PCRX?icid=chart-PCRX-fundamental/pe-ratio-ttm">Pacira BioSciences, Inc. Quote</a>
</div>
EZCORP, Inc. EZPW: This pawn services company carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 3.2% over the last 60 days.
<div class="chart_embed">
<h3>EZCORP, Inc. Price and Consensus</h3>
<a href="https://www.zacks.com/stock/chart/EZPW/price-consensus-chart?icid=chart-EZPW-price-consensus-chart"><img alt="EZCORP, Inc. Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/f4/1739262742.png" style="height:264px; width:568px" title="" /> </a>
<a href="https://www.zacks.com/stock/chart/EZPW/price-consensus-chart?icid=chart-EZPW-price-consensus-chart">EZCORP, Inc. price-consensus-chart</a> | <a href="https://www.zacks.com/stock/quote/EZPW?icid=chart-EZPW-price-consensus-chart">EZCORP, Inc. Quote</a>
</div>
Ezcorp has a price-to-earnings ratio (P/E) of 10.33, compared with 15.30 for the industry. The company possesses a Value Score of A.
<div class="chart_embed">
<h3>EZCORP, Inc. PE Ratio (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ttm#NYSE">TTM</a>)</h3>
<a href="https://www.zacks.com/stock/chart/EZPW/fundamental/pe-ratio-ttm?icid=chart-EZPW-fundamental/pe-ratio-ttm">TTM</a>)&quot; height=&quot;251&quot; src=&quot;https://staticx-tuner.zacks.com/images/charts/b8/1739262981.png&quot; title=&quot;&quot; width=&quot;532&quot; /&gt;
<a href="https://www.zacks.com/stock/chart/EZPW/fundamental/pe-ratio-ttm?icid=chart-EZPW-fundamental/pe-ratio-ttm">EZCORP, Inc. pe-ratio-ttm</a> | <a href="https://www.zacks.com/stock/quote/EZPW?icid=chart-EZPW-fundamental/pe-ratio-ttm">EZCORP, Inc. Quote</a>
</div>
&nbsp;
See <a href="https://www.zacks.com/stocks/buy-list/?ADID=zp_1link&amp;ICID=zpi%20_1link">the full list of top ranked stocks here.</a>
&nbsp;
Learn more about the <a href="https://www.zacks.com/education/stock-scorecard/value-trading">Value score and how it is calculated here.</a>
&nbsp;
<h2>Only $1 to See All Zacks&#39; Buys and Sells</h2>
We&#39;re not kidding.
Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.
Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like&nbsp;Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.
<a href="https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/6328?adid=SYND_BENZ_ZU_ZU_ZACKS1RANKADDITIONS_268_02112025_2413286&amp;cid=CS-BENZ-FT-zacks_1_rank_additions|value_additions-2413286" style="font-weight:bold">See Stocks Now &gt;&gt;</a>
&nbsp;
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. <a href="https://www.zacks.com/registration/pfp/?ALERT=RPT_7BST_LP194&amp;ADID=SYND_BENZ_7BEST_ZACKS1RANKADDITIONS_268_2413286&amp;cid=CS-BENZ-FT-zacks_1_rank_additions|value_additions-2413286" target="_blank">Click to get this free report</a>

&nbsp; 
<a href="https://www.zacks.com/registration/pfp?ALERT=ZER_LINK&amp;t=EZPW&amp;ADID=SYND_BENZ_TCK_ZACKS1RANKADDITIONS_268_2413286_EZPW&amp;cid=CS-BENZ-FT-zacks_1_rank_additions|value_additions-2413286">EZCORP, Inc. (NASDAQ: </a><a class="ticker" href="https://www.benzinga.com/stock/ezpw#NASDAQ">EZPW</a>): Free Stock Analysis Report 
&nbsp; 
<a href="https://www.zacks.com/registration/pfp?ALERT=ZER_LINK&amp;t=PCRX&amp;ADID=SYND_BENZ_TCK_ZACKS1RANKADDITIONS_268_2413286_PCRX&amp;cid=CS-BENZ-FT-zacks_1_rank_additions|value_additions-2413286">Pacira BioSciences, Inc. (NASDAQ: </a><a class="ticker" href="https://www.benzinga.com/stock/pcrx#NASDAQ">PCRX</a>): Free Stock Analysis Report 
&nbsp; 
<a href="https://www.zacks.com/registration/pfp?ALERT=ZER_LINK&amp;t=OMVKY&amp;ADID=SYND_BENZ_TCK_ZACKS1RANKADDITIONS_268_2413286_OMVKY&amp;cid=CS-BENZ-FT-zacks_1_rank_additions|value_additions-2413286">OMV AG (OMVKY): Free Stock Analysis Report</a>
<a href="https://www.zacks.com/commentary/2413286/best-value-stocks-to-buy-for-february-11th?cid=CS-BENZ-FT-zacks_1_rank_additions|value_additions-2413286">To read this article on Zacks.com click here.</a>
<a href="https://www.zacks.com/">Zacks Investment Research</a>

Equities

Small Cap

Markets

EZPW

PCRX

Best Value Stocks To Buy For February 11th

8 analysts have shared their evaluations of Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $24.62, along with a high estimate of $39.00 and a low estimate of $16.00. Observing a 15.15% increase, the current average has risen from the previous average price target of $21.38. 
<img src="https://www.benzinga.com/files/images/story/2025/1738274416_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive Pacira BioSciences is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Les Sulewski</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$25.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$18.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Oren Livnat</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$39.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Balaji Prasad</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$17.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$16.00</td>
<td>$15.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Pacira BioSciences. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Pacira BioSciences compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Pacira BioSciences's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Pacira BioSciences's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PCRX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Pacira BioSciences analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About Pacira BioSciences</h2>
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.
<h3>Financial Insights: Pacira BioSciences</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Pacira BioSciences's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 2.83%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Pacira BioSciences's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -85.11%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Pacira BioSciences's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -17.62%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -9.06%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Pacira BioSciences's debt-to-equity ratio is below the industry average. With a ratio of 0.86, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

What 8 Analyst Ratings Have To Say About Pacira BioSciences

Truist Securities analyst Les Sulewski upgrades Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) from Sell to Hold and raises the price target from $8 to $25.

News

Upgrades

Price Target

Truist Securities Upgrades Pacira BioSciences to Hold, Raises Price Target to $25

-- Accomplished Business and Financial Leader, Laura Brege, Appointed Chair --
-- Paul J. Hastings and Andreas Wicki, PhD Retire from Board of Directors --
PARSIPPANY, N.J., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that Laura Brege has been appointed Chair of the Board. Former Chair Paul J. Hastings and Andreas Wicki, PhD. have retired from the Board. These changes align with Pacira's ongoing commitment to Board refreshment. With these changes, the Board is composed of nine directors, eight of whom are independent and five of whom have joined since October 2023. Each director brings expertise in areas important to Pacira's business to support Pacira's 5x30 growth-oriented plan including executive leadership, M&amp;A, research and development, operations, commercialization, manufacturing and supply chain.

Management

Pacira Announces That Laura Brege Has Been Appointed Chair Of The Board

RBC Capital analyst Gregory Renza reiterates Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) with a Sector Perform and maintains $18 price target.

Reiteration

RBC Capital Reiterates Sector Perform on Pacira BioSciences, Maintains $18 Price Target

In the last three months, 6 analysts have published ratings on Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>), offering a diverse range of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $25.67, a high estimate of $39.00, and a low estimate of $16.00. Marking an increase of 6.21%, the current average surpasses the previous average price target of $24.17. 
<img src="https://www.benzinga.com/files/images/story/2025/1736776826_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A clear picture of Pacira BioSciences's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Oren Livnat</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$39.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Balaji Prasad</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$17.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$16.00</td>
<td>$15.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Pacira BioSciences. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Pacira BioSciences compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Pacira BioSciences's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Pacira BioSciences's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/PCRX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Pacira BioSciences analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know Pacira BioSciences Better</h2>
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.
<h3>Unraveling the Financial Story of Pacira BioSciences</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, Pacira BioSciences showcased positive performance, achieving a revenue growth rate of 2.83% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -85.11%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Pacira BioSciences's ROE excels beyond industry benchmarks, reaching -17.62%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Pacira BioSciences's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -9.06%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Pacira BioSciences's debt-to-equity ratio is below the industry average. With a ratio of 0.86, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Significance of Analyst Ratings Explained</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

6 Analysts Assess Pacira BioSciences: What You Need To Know

Needham analyst Serge Belanger maintains Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) with a Buy and raises the price target from $22 to $30.

Needham Maintains Buy on Pacira BioSciences, Raises Price Target to $30

U.S. stocks were lower, with the Dow Jones index falling over 700 points on Friday.
Shares of TD Synnex Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNX#NYSE">SNX</a>) rose sharply in today's session after the company reported <a href="https://www.benzinga.com/25/01/42915528/td-synnex-shares-delivers-earnings-beat-and-boosts-dividend-by-10">better-than-expected quarterly financial results.</a>
Quarterly revenue of $15.85 billion, up 10% Y/Y, exceeded the analyst view of $15.22 billion. The Fremont, California-based company reported an adjusted EPS of $3.09, beating the street view of $3.05.
TD Synnex shares jumped 5.5% to $128.76 on Friday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Microvast Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVST#NASDAQ">MVST</a>) shares jumped 37.3% to $2.57 after the company announced a developments in its True All-Solid-State Battery technology.</li>
<li>Walgreens Boots Alliance Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) gained 23.6% to $11.40 after the company reported better-than-expected first-quarter financial results.</li>
<li>Savers Value Village Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SVV#NYSE">SVV</a>) surged 13.5% to $10.63 after the company reported preliminary fourth quarter and full year net sales.</li>
<li>Oculis Holding AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCS#NASDAQ">OCS</a>) gained 13.1% to $21.14.</li>
<li>Sasol Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSL#NYSE">SSL</a>) gained 13.1% to $4.99.</li>
<li>Pacira Biosciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) climbed 12.1% to $20.83 after the company reported a preliminary year-over-year increase in FY25 revenue.</li>
<li>Royalty Pharma plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>) gained 10.6% to $28.97 after the company announced it increased its quarterly dividend.</li>
<li>Merus NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) gained 9.8% to $46.35.</li>
<li>Teekay Tankers Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TNK#NYSE">TNK</a>) rose 8.1% to $45.56.</li>
<li>Talos Energy Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TALO#NYSE">TALO</a>) gained 6.2% to $10.58.</li>
<li>TD Synnex Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNX#NYSE">SNX</a>) rose 5.5% to $128.76 after the company reported better-than-expected quarterly financial results.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42912948/top-3-materials-stocks-that-are-set-to-fly-this-month">Top 3 Materials Stocks That Are Set To Fly This Month</a></li>
</ul>

Intraday Update

Movers

Trading Ideas

MRUS

MVST

RPRX

TALO

TD Synnex, Walgreens, Savers Value Village And Other Big Stocks Moving Higher On Friday

WIIM

Pacira Biosciences shares are trading higher after the company reported a preliminary year-over-year increase in FY25 revenue.

5x30 Path to growth and value creation
The company intends to achieve the following five objectives by 2030 ("5x30"):
<ul>
<li>Patients: More than three million patients treated per year</li>
<li>Product revenue: Double-digit compounded annual growth rate</li>
<li>Profitability: Five percentage point gross margin improvement over 2024</li>
<li>Pipeline: Clinical pipeline expansion with five novel programs in development</li>
<li>Partnerships: Establishing five partnerships including pipeline and commercial agreements</li>
</ul>

Guidance

Pacira Reports Prelim. 2024 Revenue Of $710M vs $675.0M YoY; Co. Sets 2030 Goals Including More Than 3M Patients Treated Yearly

On Tuesday, Pacira BioSciences, Inc.&nbsp; (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) received FDA clearance to market a new Smart Tip designed to access the medial branch nerves to manage chronic <a target="_blank" href="https://www.benzinga.com//node/42841844" rel="noreferrer noopener">low back pain</a>.
The ioveraº system is a drug-free treatment that relieves pain via cryoneurolysis—a process whereby focused cold therapy is applied to a targeted nerve, temporarily interrupting its ability to transmit pain signals.
Pain relief is typically experienced immediately after treatment, lasting for months as the nerve regenerates.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40321378/pain-management-focused-pacira-biosciences-loses-patent-fight-for-key-drug-jp-morga" rel="noreferrer noopener">Pain Management-Focused Pacira BioSciences Loses Patent Fight For Key Drug, JP Morgan Analyst Downgrades On Unclear Path</a>
To date, the ioveraº portfolio has consisted of either a three-pronged Smart Tip featuring 8.5-mm long 27-gauge needles to treat superficial nerves or a single, 90-mm long, 20-guage Smart Tip ideally suited to treat deeper nerves.
It is most commonly used to treat knee pain but frequently used to manage pain in the hip, shoulder, chest, foot &amp; ankle, and more.
This new, 25-gauge 180-mm Smart Tip will allow for the treatment of deeper nerves, such as the medial branch nerve. It is specifically designed to relieve chronic low back pain associated with facet-mediated pain.
This longer-needle Smart Tip is designed for use through a cannula or introducer, allowing ice ball formation at deeper peripheral nerves.
Annually, 28 to 30 million Americans seek treatment for chronic back pain, yet only 2 to 3 million undergo interventional procedures.
With the introduction of this new iovera° Smart Tip, Pacira aims to address these gaps and elevate the standard of care.
The company adds that the product offers an alternative to conventional treatments, such as radiofrequency ablation, with substantial limitations.
A single-center randomized pilot study of the iovera° system showed:
<ul>
<li>Patients treated with iovera° reported pain scores more than 2 points lower at 180 and 360 days than those treated with RFA on the 0-10 NRS Pain scale.</li>
<li>At 360 days, patients in the iovera° group showed statistically and clinically significant improvements in functional outcomes, as evidenced by average Oswestry Disability Index (ODI) scores improving from moderate to minimal disability.</li>
<li>More iovera° patients expressed satisfaction with their pain management compared to those receiving RFA.</li>
<li>No serious adverse events were observed over the course of the study.</li>
</ul>
Price Action: PCRX stock is up 1.50% at $18.91 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42846580/rpm-international-q2-strong-sales-adjusted-ebit-growth-and-updated-fy25-guidance" target="_blank" rel="noreferrer noopener">Paint &amp; Coating Company RPM Beats Q2 Expectations But Signals Flat Q3; Stock Dips</a></li>
</ul>

Health Care

General

Pacira BioSciences Secures FDA Approval For New iovera SmartTip to Manage Chronic Low Back Pain

Pacira Biosciences shares are trading higher after the company announced it received FDA 510k clearance to market its new iovera° SmartTIp for chronic lower back pain via a medial branch nerve block.

Pacira BioSciences Receives FDA 510k Clearance To Market New iovera° SmartTip For Chronic Low Back Pain via Medial Branch Nerve Block

Across the recent three months, 6 analysts have shared their insights on Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $21.17, a high estimate of $39.00, and a low estimate of $15.00. Highlighting a 2.31% decrease, the current average has fallen from the previous average price target of $21.67. 
<img src="https://www.benzinga.com/files/images/story/2024/1733313644_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Pacira BioSciences among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oren Livnat</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$39.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Balaji Prasad</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$17.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$16.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$15.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Glen Santangelo</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$18.00</td>
<td>$15.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Pacira BioSciences. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Pacira BioSciences compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Pacira BioSciences's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Pacira BioSciences's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/PCRX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Pacira BioSciences analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About Pacira BioSciences</h2>
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.
<h3>Key Indicators: Pacira BioSciences's Financial Health</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Pacira BioSciences showcased positive performance, achieving a revenue growth rate of 2.83% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Pacira BioSciences's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -85.11%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Pacira BioSciences's ROE excels beyond industry benchmarks, reaching -17.62%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Pacira BioSciences's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -9.06%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Pacira BioSciences's debt-to-equity ratio is below the industry average. With a ratio of 0.86, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Decoding 6 Analyst Evaluations For Pacira BioSciences

HC Wainwright &amp; Co. analyst Oren Livnat reiterates Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) with a Buy and maintains $39 price target.

HC Wainwright & Co. Reiterates Buy on Pacira BioSciences, Maintains $39 Price Target

Biotech

Pacira Biosciences Received U.S. Patent No. 12,156,940 From The U.S. Patent And Trademark Office, Which Protects The Chemical Composition Of Exparel (Bupivacaine Liposome Injectable Suspension). The Company Expects The '940 Patent To Provide Protection Into July 2044

Pacira Secures New U.S. Patent For EXPAREL Composition, Expanding IP Protection Through 2044

Pacira Reports 104-Week Safety And Efficacy Data Following Local Administration Of PCRX-201 For Moderate To Severe Osteoarthritis Of Knee

Barclays analyst Balaji Prasad maintains Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) with a Equal-Weight and lowers the price target from $25 to $17.

Barclays Maintains Equal-Weight on Pacira BioSciences, Lowers Price Target to $17

Needham analyst Serge Belanger reiterates Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) with a Buy and maintains $22 price target.

Needham Reiterates Buy on Pacira BioSciences, Maintains $22 Price Target

Full-year EXPAREL net product sales of $549.0 million in 2024, compared with $538.1 million in 2023. Full-year net product sales were comprised of ...

Pacira sees FY24 revenue $701M, consensus $695.18M

Needham analyst Serge Belanger maintained a Buy rating on Pacira Pharmaceuticals (PCRX – Research Report) today and set a price target of $30.00. S...

Pacira Pharmaceuticals: Strong Growth Prospects and Strategic Goals Drive Buy Rating

Needham raised the firm's price target on Pacira (PCRX) to $30 from $22 and keeps a Buy rating on the shares. The firm cites the company's "solid" ...

Pacira price target raised to $30 from $22 at Needham

THE LAWSUIT: A class action securities lawsuit was filed against Pacira BioSciences, Inc. (PCRX) that seeks to recover losses of Pacira shareholder...

Shareholders that lost money on Pacira BioSciences, Inc.(PCRX) should contact Levi & Korsinsky LLP about pending Class Action – PCRX

Pacira Pharmaceuticals ( ($PCRX) ) has provided an announcement. On January 21, 2025, Pacira BioSciences announced two key leadership appointments ...

Pacira Pharmaceuticals Announces Leadership Changes and Plan Amendment

Barclays analyst Balaji Prasad maintained a Hold rating on Pacira Pharmaceuticals (PCRX – Research Report) today and set a price target of $17.00. ...

Barclays Reaffirms Their Hold Rating on Pacira Pharmaceuticals (PCRX)

Truist upgraded Pacira (PCRX) to Hold from Sell with a $25 price target Published first on TheFly – the ultimate source for real-time, market-movin...

Pacira upgraded to Hold from Sell at Truist

Pacira Pharmaceuticals ( ($PCRX) ) has issued an announcement. On January 28, 2025, Pacira BioSciences announced significant changes to its Board o...

Pacira Pharmaceuticals Implements New Board Leadership for Growth

Pacira (PCRX) BioSciences announced that Laura Brege has been appointed Chair of the Board. Former Chair Paul J. Hastings and Andreas Wicki, PhD. h...

Pacira announces Board Chair Hastings retired, Brege to succeed

Pacira upgraded at Truist citing end to eVenus patent dispute

Press Releases

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Legal

Class Action Filed Against Pacira BioSciences, Inc. (PCRX) Seeking Recovery for Investors – Contact The Gross Law Firm

PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit

Shareholders that lost money on Pacira BioSciences, Inc.(PCRX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira

Shareholders that lost money on Pacira BioSciences, Inc.(PCRX) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More

PACIRA BIOSCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRX

ROSEN, LEADING INVESTOR COUNSEL, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PCRX

Comments

Pacira BioSciences

ニュース

最新ニュース Pacira BioSciences (NASDAQ:PCRX) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル